<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04749901</url>
  </required_header>
  <id_info>
    <org_study_id>2020-42</org_study_id>
    <secondary_id>ID-RCB</secondary_id>
    <nct_id>NCT04749901</nct_id>
  </id_info>
  <brief_title>Symptoms of Post-traumatic Stress in Adult Drug-resistant Epilepsies</brief_title>
  <acronym>SPIRALE</acronym>
  <official_title>Symptoms of Post-traumatic Stress in Adult Drug-resistant Epilepsies: Incidence and Influence on Cognitive Control Capacities and on Seizure Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epilepsy is a neurological disease that can cause many comorbid psychiatric disorders, among&#xD;
      them: generalized anxiety disorder and depression. Many studies suggest a temporal&#xD;
      relationship between exposure to a traumatic event and the development of epilepsy. The&#xD;
      objective of this research is to study the symptoms of post-traumatic stress disorder (PTS)&#xD;
      in patients with epilepsy, and their relation to anxiety and depression in these patients.&#xD;
      The investigators also wish to study how such symptoms may be associated with the subjective&#xD;
      semiological manifestations of epileptic seizures. In addition, it has been shown that&#xD;
      patients with epilepsy are able, from the identification of different warning signs, to&#xD;
      anticipate their vulnerability to having an epileptic seizure allowing them to set up&#xD;
      different types. strategies to control them. The investigators also wish to study the&#xD;
      cognitive processes involved in this control and the influence of PTS symptoms, in particular&#xD;
      hypervigilance on this behavior.&#xD;
&#xD;
      The investigators propose a protocol using different types of measures: emotional, cognitive&#xD;
      and physiological in order to answer our questions. In addition to patients with epilepsy,&#xD;
      two groups of patients will be included: a group of patients with another chronic&#xD;
      non-neurological disease to compare the prevalence of PTS symptoms and a group of patients&#xD;
      with post-traumatic stress disorder ( PTSD) to compare with patients with epilepsy, cognitive&#xD;
      and physiological measures.&#xD;
&#xD;
      Finally, the results of this study should allow to develop tools for assessing PTS symptoms&#xD;
      in epilepsy and to develop specific management approaches&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anxiety level</measure>
    <time_frame>Baseline</time_frame>
    <description>Beck Anxiety inventory (0-63), higher values mean worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depression</measure>
    <time_frame>Baseline</time_frame>
    <description>Beck Anxiety inventory (0-21), higher values mean worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with PTSD</measure>
    <time_frame>Baseline</time_frame>
    <description>Post-traumatic stress disorder</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Emotion regulation</measure>
    <time_frame>Baseline</time_frame>
    <description>The difficulties in emotion regulation scale,(0-180), higher values mean better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life of the patient</measure>
    <time_frame>Baseline</time_frame>
    <description>Medical Outcome Study and 36-item Short Form Health Survey (0-60),higher values mean worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seizures control</measure>
    <time_frame>Baseline</time_frame>
    <description>Seizure control scale (0-85), higher values mean better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seizures control (heart rythm)</measure>
    <time_frame>Baseline</time_frame>
    <description>HRSC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PTSD</measure>
    <time_frame>Baseline</time_frame>
    <description>PTSD-E (0-100), higher values mean worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Emotionnal control of diabete</measure>
    <time_frame>Baseline</time_frame>
    <description>DID-C (Diabete insulino-dependant-Control) (elaborated for the study) (0-150), higher values mean worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Emotionnal control of diabete and PTSD</measure>
    <time_frame>Baseline</time_frame>
    <description>DID-PTSD (Diabete insulino-dependant-Posttraumatic Stress Disorder) (elaborated for the study) (0-185), higher values mean worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin conductance</measure>
    <time_frame>Baseline</time_frame>
    <description>BIOPAC SCL (EDA 100C)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Eyes movements</measure>
    <time_frame>Baseline</time_frame>
    <description>EyeLink 1000 (SR Research)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rythm variability</measure>
    <time_frame>Baseline</time_frame>
    <description>BIOPAC ECG (EL250)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Attentional and executive control</measure>
    <time_frame>Baseline</time_frame>
    <description>Attentional and executive control task in the context of hypervigilance (elaborated for the study) (0-180), higher values mean worse outcome</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Patients with epilepsy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with PTSD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with type 1 diabetes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with a heart rhythm disorder</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Psycho-emotional and semiological measures</intervention_name>
    <description>Surveys, interviews and measures</description>
    <arm_group_label>Patients with PTSD</arm_group_label>
    <arm_group_label>Patients with a heart rhythm disorder</arm_group_label>
    <arm_group_label>Patients with epilepsy</arm_group_label>
    <arm_group_label>Patients with type 1 diabetes</arm_group_label>
    <other_name>Cognitive measures</other_name>
    <other_name>Physiological measurements</other_name>
    <other_name>Qualitative measures</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman between 18 and 50 years old;&#xD;
&#xD;
          -  Native French speaker;&#xD;
&#xD;
          -  Level of education higher than the 3rd school level;&#xD;
&#xD;
          -  Certain diagnosis of the pathology of the experimental group with which he will be&#xD;
             associated, more precisely:&#xD;
&#xD;
          -  Group of patients with epilepsy [Group E]: definite diagnosis of drug-resistant&#xD;
             epilepsy (epileptic seizures persist despite the administration of daily treatment)&#xD;
             established by a specialist physician.&#xD;
&#xD;
          -  Group of patients with a heart rhythm disorder [Group C]: definite diagnosis of one of&#xD;
             the following disorders: Atrial Fibrillation (AF); Syncope and Bouveret's disease&#xD;
             established by a specialist.&#xD;
&#xD;
          -  Group of patients with T1 diabetes mellitus [Group D]: definite diagnosis of type 1&#xD;
             diabetes established by a specialist doctor.&#xD;
&#xD;
          -  Group of patients with PTSD [Group T]: definite diagnosis of PTSD established by a&#xD;
             specialist doctor.&#xD;
&#xD;
          -  Person having given his non-objection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy;&#xD;
&#xD;
          -  Breastfeeding women;&#xD;
&#xD;
          -  Severe cognitive impairment&#xD;
&#xD;
          -  Addiction to alcohol or drugs (including drugs other than those related to epilepsy or&#xD;
             the chronic disease from which the patient has);&#xD;
&#xD;
          -  Other neurological and / or psychiatric disorders than CNEP or epilepsy except anxiety&#xD;
             and depressive disorders;&#xD;
&#xD;
          -  Adults under guardianship or under judicial protection&#xD;
&#xD;
          -  People deprived of their liberty&#xD;
&#xD;
          -  Inability to read French.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Olivier ARNAUD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrice Bartolomei</last_name>
    <phone>0491385829</phone>
    <phone_ext>33</phone_ext>
    <email>fabrice.bartolomei@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice Bartolomei</last_name>
      <phone>491385829</phone>
      <phone_ext>33</phone_ext>
      <email>fabrice.bartolomei@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Claude DE HARO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrice DARMON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier ZENDJIDJIAN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>October 3, 2021</last_update_submitted>
  <last_update_submitted_qc>October 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

